Evolus Historical Income Statement
| EOLS Stock | USD 11.56 0.08 0.69% |
Historical analysis of Evolus income statement accounts such as Selling General Administrative of 84.8 M or Total Revenue of 212.2 M can show how well Evolus Inc performed in making a profits. Evaluating Evolus income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Evolus's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Evolus Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Evolus Inc is a good buy for the upcoming year.
Evolus |
About Evolus Income Statement Analysis
Evolus Inc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Evolus shareholders. The income statement also shows Evolus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Evolus Income Statement Chart
Evolus Inc Income Statement is one of the three primary financial statements used for reporting Evolus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Evolus Inc revenue and expense. Evolus Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Evolus' Non Operating Income Net Other is comparatively stable compared to the past year. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Evolus Inc. It is also known as Evolus overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Evolus' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Evolus Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Evolus' Non Operating Income Net Other is comparatively stable compared to the past year.
Evolus income statement Correlations
Click cells to compare fundamentals
Evolus Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Evolus income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.8M | 9.7M | (667K) | (1.9M) | 5.9M | 6.2M | |
| Interest Expense | 8.0M | 10.5M | 1.4M | 9.1M | 13.8M | 14.5M | |
| Selling General Administrative | 113.6M | 98.2M | 118.4M | 147.6M | 164.9M | 84.8M | |
| Total Revenue | 34.9M | 56.5M | 99.7M | 148.6M | 202.1M | 212.2M | |
| Gross Profit | 26.9M | 38.2M | 56.1M | 92.7M | 135.4M | 142.2M | |
| Other Operating Expenses | 129.7M | 125.2M | 163.3M | 206.2M | 238.2M | 250.1M | |
| Operating Income | (94.8M) | (68.7M) | (63.6M) | (57.6M) | (36.1M) | (37.9M) | |
| Net Income From Continuing Ops | (90.0M) | (163.0M) | (46.8M) | (74.4M) | (61.7M) | (64.8M) | |
| Ebit | (94.8M) | (68.7M) | (63.6M) | (57.6M) | (36.1M) | (37.9M) | |
| Research Development | 4.0M | 1.7M | 2.1M | 4.7M | 6.6M | 5.8M | |
| Ebitda | (93.0M) | (59.0M) | (64.3M) | (59.5M) | (30.2M) | (31.8M) | |
| Cost Of Revenue | 8.0M | 18.3M | 43.5M | 55.9M | 66.7M | 70.0M | |
| Total Operating Expenses | 121.7M | 106.9M | 119.8M | 150.3M | 171.5M | 93.9M | |
| Income Before Tax | (105.1M) | (162.9M) | (46.8M) | (74.3M) | (61.5M) | (64.6M) | |
| Total Other Income Expense Net | (10.3M) | (94.2M) | 16.8M | (16.7M) | (25.4M) | (24.1M) | |
| Net Income Applicable To Common Shares | (90.0M) | (163.0M) | (46.8M) | (74.4M) | (67.0M) | (70.3M) | |
| Net Income | (90.0M) | (163.0M) | (46.8M) | (74.4M) | (61.7M) | (64.8M) | |
| Income Tax Expense | (15.0M) | 77K | 42K | 95K | 176K | 184.8K | |
| Tax Provision | (15.0M) | 77K | 42K | 95K | 176K | 184.8K | |
| Reconciled Depreciation | 5.0M | 7.7M | 6.3M | 4.5M | 5.9M | 4.7M | |
| Net Interest Income | (6.1M) | (9.9M) | (1.4M) | (9.0M) | (13.0M) | (12.3M) | |
| Interest Income | 1.8M | 635K | 1K | 119K | 860K | 487.6K |
Pair Trading with Evolus
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evolus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evolus will appreciate offsetting losses from the drop in the long position's value.Moving together with Evolus Stock
| 0.67 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Evolus Stock
| 0.74 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
| 0.67 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.6 | VIRI | Virios Therapeutics Llc Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Evolus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evolus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evolus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evolus Inc to buy it.
The correlation of Evolus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evolus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evolus Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evolus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Evolus Stock analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Evolus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolus. If investors know Evolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share 3.55 | Quarterly Revenue Growth 0.398 | Return On Assets (0.12) | Return On Equity (12.79) |
The market value of Evolus Inc is measured differently than its book value, which is the value of Evolus that is recorded on the company's balance sheet. Investors also form their own opinion of Evolus' value that differs from its market value or its book value, called intrinsic value, which is Evolus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolus' market value can be influenced by many factors that don't directly affect Evolus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.